Basal Vitamin D Status and Supplement Dose Are Primary Contributors to Maternal 25-Hydroxyvitamin D Response to Prenatal and Postpartum Cholecalciferol Supplementation.

Plain-language guide to PMID 34302350 (2021): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Key Facts

PMID: 34302350
Journal: The Journal of nutrition
Year: 2021
Study type: Randomized Controlled Trial
Authors: Levy B et al. (7 authors)
DOI: 10.1093/jn/nxab265

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in this randomized controlled trial publication.

The researchers aimed to examine interindividual variation in maternal and infant 25(OH)D following maternal vitamin D supplementation.

Who Took Part

The age groups tagged for this paper are infants, women only.

In a subset of participants, associations of 25(OH)D with hypothesized explanatory factors were estimated in women at delivery (n = 655) and 6 mo postpartum (n = 566), and in their infants at birth (n = 502) and 6 mo of age (n = 215).

Multivariable models were extended to include other individual characteristics and specimen-related factors.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

The model coefficient of determination (R2) was used to express the percentage of total variance explained.

What Was Measured

PubMed files the paper under topics including Cholecalciferol, Dietary Supplements, Postpartum Period, Vitamin D and Vitamin D Deficiency.

Author keywords: 25-hydroxyvitamin D, infancy, pregnancy and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (The Journal of nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.

Our Notes on the Compounds

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.